Editorial Methodology & Scoring Rubric
Released: Last reviewed: Updated:
One current methodology governs provider scoring, ranking tables, FAQ answers, datasets, and llms files.
Seven weighted categories
| Category | Weight |
|---|---|
| Pricing transparency | 20% |
| Total annual cost | 20% |
| Clinical oversight | 15% |
| Pharmacy transparency | 15% |
| Support | 10% |
| Regulatory disclosure | 10% |
| Accessibility | 10% |
Affordability inclusion rule
A provider is ranked in the verified standard-injection affordability table only when its complete 12-month all-in standard-injection cost can be verified from a standing public source.
A starting price multiplied by twelve is labeled a floor, not a verified annual total, unless the provider confirms on a standing public page that the price remains applicable across covered doses and that required fees and included services are disclosed.
Source hierarchy
- Standing first-party pricing and program pages.
- Written provider terms, clinician disclosures, and pharmacy disclosures.
- FDA, state licensing, and pharmacy-board records.
- Peer-reviewed evidence and official prescribing information for clinical claims.
- Third-party reports and patient reviews as context only, clearly labeled and never used as the sole basis for a verified price.
Editorial roles
Dr. Parmis serves as Editorial Lead. Dr. Jonathan Snipes, MD (NPI 1821250077) serves as Medical Reviewer, and Kim Callender, NP (FNP-BC, NPI 1144661760) serves as Lead Reviewer. Provider representatives have no editorial role in provider evaluations.
Affiliate and conflict disclosure
TirzepatideReview.com is published by Ronika Partners LLC and is affiliate-supported. The publisher may receive compensation when readers enroll through certain provider links. Providers cannot purchase placement or alter a score. Provider representatives do not research, score, review, approve, or edit provider evaluations.
Corrections
Send documented corrections to corrections@tirzepatidereview.com. We target review within five business days and update material errors when verified.
Update cadence
- Pricing evidence is rechecked on a rolling basis and date-stamped.
- Rankings are recalculated when verified facts materially change.
- The methodology is reviewed at least quarterly and after material regulatory or evidence changes.
- Only the current public version, v4.1, is used in live rankings and machine-readable files.
Machine-readable resources
Medical note: The site is educational and does not provide medical care. Compounded medications are not FDA-approved drug products. Treatment decisions require evaluation by a licensed clinician.
Frequently asked questions
How does TirzepatideReview.com rank providers?
On a published seven-category rubric: pricing transparency 20%, total annual cost 20%, clinical oversight 15%, pharmacy transparency 15%, support 10%, regulatory disclosure 10% and accessibility 10%. Providers cannot pay for placement.
Who reviews the content?
Pages are researched by Dr. Parmis and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).
Does the site earn money from providers?
The site is affiliate-supported and may earn a referral commission; compensation does not change scores, rankings or reported prices. See the disclosure in the footer.
What we look for in each of the seven categories
The weights below are the v4.1 weights already published on this page, written as points out of 100. The evidence column lists what a reviewer checks in that category. These are the same items that appear in every review's at-a-glance table and in each "vs NexLife" comparison.
| Category | Points | Evidence we check |
|---|---|---|
| Pricing transparency | 20 | Is the standing price printed before checkout? Is the billing basis stated (monthly, every 4 weeks, prepaid once)? Are membership, consult and shipping fees itemized? Does the site state its dose policy? Does the site show conflicting "from" prices? Are cancellation and refund terms published before checkout? |
| Total annual cost | 20 | The verified 12-month all-in standard-injection cost: medication, required clinician services, lab review when included, support, required membership and shipping |
| Clinical oversight | 15 | A named medical director; a statement that licensed clinicians review every intake; whether labs are ordered and reviewed |
| Pharmacy transparency | 15 | Whether the dispensing pharmacy is named before you pay, so its license and FDA record can be checked; whether the drug's additives are stated |
| Support | 10 | Access to clinicians and care staff between visits; coaching or nutrition support included in the price |
| Regulatory disclosure | 10 | A clear statement that compounded drugs are not FDA-approved; claims checked against FDA warning letters to the provider |
| Accessibility | 10 | States served; insurance, HSA/FSA and Medicare position |
For example, our #1 program, NexLife, is rewarded for keeping one price from 2.5 mg to 15 mg, naming its pharmacies on its plan pages and naming its medical director. Programs that leave out the pharmacy, the consultation fee or lab costs lose points in those categories. No category depends on a provider's commercial relationship with us.
How are prices read, dated and labeled?
- Source. Every price is read on the provider's own public page and recorded with its billing basis, membership and consult fees, dose policy, source URL and read date. Third-party reports and patient reviews are context only and never the sole basis for a verified price.
- Dates. Pages show the read date beside the figure, for example "read November 4, 2026." Rows we could not re-read keep their last read date and are never averaged with newer figures. Open items are tracked on the verification queue.
- Labels. Introductory, starter-dose, promotional and medication-only figures are labeled as such and kept apart from verified all-in annual totals.
- Floors. A starting price multiplied by twelve is shown as a floor, not a verified annual total, unless the provider states on a standing page that the price holds across doses and lists all required fees.
Two cases from the November 4, 2026 re-read show how the floor rule works. Mochi Health prices medication by dose and adds a membership, so its lowest-dose figure is a floor. WellMedr says its multi-month plans are prepaid in full but did not print the per-plan totals, so its 12-month cost could not be verified. The open pricing methodology and datasets use the same rules.
Corrections, conflicts of interest and affiliate links
Corrections. Send the page URL, the sentence you believe is wrong and a source we can check to corrections@tirzepatidereview.com. We aim to review documented corrections within five business days. Material errors are fixed once verified and logged on the affected page with the date. Example: the Red Rock Pharmacy profile states that earlier editions gave the wrong city, founding date and accreditation. When a corrected fact changes a score, rankings are recalculated.
Funding. TirzepatideReview.com is published by Ronika Partners LLC and is affiliate-supported. The publisher may earn a commission when a reader enrolls through certain provider links, at no extra cost to the reader. Commission relationships can exist with one or more listed providers and can change. They never decide a position. Outbound provider links carry rel="nofollow", and any paid placement would be labeled where it appears.
Independence. Providers cannot buy placement or change a score, and provider representatives do not research, score, review, approve or edit evaluations. The Editorial Lead receives no compensation from any provider reviewed. Every program, the #1 pick included, can lose its position if verified facts change. See About for ownership details.
More questions
What happens to a score when a provider changes its price?
The new price is read on the provider's own page, dated and recorded. If it materially changes a category such as total annual cost, the ranking is recalculated.
Why is a provider's annual cost sometimes shown as a floor?
If a provider prints only a starting price, or does not confirm that the price holds at every dose with all required fees included, we cannot verify a full 12-month total. The starting price times twelve is then labeled a floor.
Do affiliate links change which providers appear in the price tables?
No. Every price table sorts all programs by the same published rule, and the site states which programs list lower prices than its #1 pick.
Further sources
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026)
- FDA: Compounding and the FDA: questions and answers
- FDA: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s (March 3, 2026)
- eCFR: 16 CFR Part 255, Guides Concerning the Use of Endorsements and Testimonials in Advertising
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022